We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Europe Allows Sale of Genetically Modified Corn

By Biotechdaily staff writers
Posted on 25 May 2004
Despite reservations on the part of many of the member states, the European Commission has announced it will allow the sale of Bt-11 sweet corn, thereby ending a six-year moratorium on the import of genetically modified (GM) food products. More...
The ruling will allow the import of Bt-11 corn already canned and ready for the supermarket shelf. Members of the European Union (EU) will not be allowed to cultivate Bt-11 sweet corn.

Bt-11 sweet corn was developed by Syngenta (Basel, Switzerland). Normal maize (Zea mays) was modified by the insertion of a gene from the bacterium Bacillus thuringiensis that produces the Bt protein Cry1Ab. When eaten by the European corn borer or corn earworm, two important sweet corn pests, digestive enzymes in the alkaline environment of the larva's intestine metabolize Cry1Ab, yielding a shorter protein that binds to the wall of the intestine. Following binding, pores are formed that disrupt midgut ion flow, causing gut paralysis and eventual death from bacterial sepsis. Cry1Ab is lethal only when eaten by the larvae of lepidopteran insects (moths and butterflies), and its specificity of action is directly attributable to the presence of specific binding sites in the target insects. There are no binding sites for the delta-endotoxins of B thuringiensis on the surface of mammalian intestinal cells. Therefore, livestock animals and humans are not susceptible to these proteins.

The safety of Bt-11 sweet corn for use as a food has been demonstrated by digestibility studies, toxicity studies, and allergenicity studies. The composition and nutritional value of Bt-11 has been shown to be comparable or substantially equivalent to non-Bt sweet corn. Objection to the use of GM corn is based primarily on anecdotal reports such as those of livestock dying of "mysterious” illnesses after having been fed genetically modified maize. Other concerns center on the genetic stability of the modified plants and on the activity of the Bt genes as they move up the food chain.

While the World Health Organization (WHO, Geneva, Switzerland) is strongly promoting GM foods as the key to preventing food shortages in the coming decades, the success of GM foods in Europe will largely be determined by the willingness of consumers to buy them.




Related Links:
Syngenta

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.